文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

微创腹左胸入路(MALTA)治疗Siewert II型食管胃结合部腺癌的围术期与肿瘤学结局

Minimally invasive abdominal and left thoracic approach (MALTA) for Siewert type II esophagogastric junction adenocarcinoma: A retrospective cohort study of perioperative and oncologic outcomes.
PubMed 文献 · Surg Endosc · 2025-10-29

该回顾性队列纳入2013至2023年16例接受MALTA的Siewert II型AEG患者,术式为腹腔镜胃切除加胸腔镜下纵隔食管切除及胸内重建,无需术中翻身。全部R0切除,中位手术时间438分钟、出血28毫升,并发症31.3%,无院内死亡;中位随访51个月,5年OS 60.2%、DFS 42.9%。

要点

  • MALTA对Siewert II型AEG可行且安全,可实现稳定胸内吻合。
  • 16例均达R0切除,术后并发症31.3%,无院内死亡。
  • 中位随访51个月,5年OS 60.2%、DFS 42.9%。

核心结论

  • MALTA对Siewert II型AEG是可行、安全且微创的选择,可在不改变患者体位下完成稳定胸内吻合。
  • 结果提示其在围术期和生存结局方面具有潜在应用价值。

研究设计与样本

  • 回顾性队列研究,纳入2013至2023年连续16例接受MALTA的Siewert II型AEG患者。
  • 术式为腹腔镜胃切除联合胸腔镜下纵隔食管切除及胸内重建,全程无需术中翻身。
  • 主要结局为可行性与安全性(R0切除率和术后并发症),次要结局为OS和DFS,采用Kaplan-Meier法估计。

主要发现

  • 全部患者实现R0切除,中位手术时间438分钟,中位出血量28毫升。
  • 术后并发症发生率31.3%,其中吻合口漏12.5%、脓胸18.8%,无院内死亡及呼吸系统并发症。
  • 中位随访51个月,1年、3年、5年OS分别为87.5%(95%CI 61.4-96.9)、67.7%(95%CI 41.8-85.9)、60.2%(95%CI 34.7-81.1)。
  • 1年、3年、5年DFS分别为68.8%(95%CI 43.3-86.4)、56.3%(95%CI 32.4-77.5)、42.9%(95%CI 21.5-67.3)。

临床怎么用

  • 对于Siewert II型AEG,MALTA可作为微创手术选项,在不改变体位下完成胸内吻合。
  • 需关注吻合口漏和脓胸等并发症,本组发生率分别为12.5%和18.8%。

局限性

  • 回顾性设计且样本量仅16例,结果需更大样本验证。
  • 单中心研究,随访时间及病例选择可能影响结论外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction (AEG) remains controversial because of the complex lymphatic spread and anatomical constraints. We previously developed a novel minimally invasive abdominal and left thoracic approach (MALTA) to overcome the limitations of conventional techniques. This study aimed to provide an updated analysis of MALTA with extended follow-up period compared with our initial report. METHOD: A retrospective review was conducted on 16 consecutive patients who underwent MALTA for Siewert type II AEG between 2013 and 2023. The procedure combined laparoscopic gastrectomy and thoracoscopic lower mediastinal esophagectomy with intrathoracic reconstruction, both of which were performed without intraoperative repositioning. Perioperative outcomes, postoperative complications, and survival rates were analyzed. The Kaplan-Meier method was used to estimate overall survival (OS) and disease-free survival (DFS). The primary outcome was feasibility and safety (R0 resection rate and postoperative complications). Secondary outcomes included OS and DFS. RESULTS: R0 resection was achieved in all patients. The median operative time was 438 min, and median blood loss was 28 mL. Postoperative complications occurred in 31.3% of the patients, including anastomotic leakage (12.5%) and empyema (18.8%). No in-hospital deaths or respiratory complications were reported. The median follow-up duration was 51 months. The 1-, 3-, and 5-year OS rates were 87.5% (95% confidence interval [CI], 61.4-96.9), 67.7% (95% CI, 41.8-85.9), and 60.2% (95% CI, 34.7-81.1), respectively. The DFS rates were 68.8% (95% CI, 43.3-86.4), 56.3% (95% CI, 32.4-77.5), and 42.9% (95% CI, 21.5-67.3), respectively. CONCLUSIONS: MALTA appears to be a feasible, safe, and minimally invasive option for Siewert type II AEG, enabling stable intrathoracic anastomosis without patient repositioning. These results suggest its potential utility in achieving favorable perioperative and survival outcomes.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Nitta T, Ebihara Y, Takagi R, et al. Minimally invasive abdominal and left thoracic approach (MALTA) for Siewert type II esophagogastric junction adenocarcinoma: A retrospective cohort study of perioperative and oncologic outcomes. Surg Endosc. 2025. PMID: 41160168. doi:10.1007/s00464-025-12320-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。